Intersex Effect of Lamotrigine on the Pharmacokinetic Parameters of CDRI-97/78, a Novel Trioxane Antimalarial Compound, in Rats

 

 Buy Article Permissions and Reprints

Abstract

Reports regarding drug toxicity and adverse events resulting from coadministration of multiple drugs are increasing at an alarming rate. CDRI-97/78 is an 1,2,4-trioxane antimalarial agent under development which gets metabolized to the in vivo active metabolite 97/63. In order to assess its drug interaction potential, CDRI-97/78 was administered alone and in combination with lamotrigine to male and female rats via the oral route. Quantification of the active metabolite 97/63 in rat plasma was achieved with an LC-MS/MS assay. After oral administration of 97/78, the T_max and C_max values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for C_max of 622.75±95.09 ng/mL and for T_max of 7.5±0.5 h. Coadministration of 97/78 and lamotrigine resulted in decreased T_max and C_max values in both male and female rats (T_max and C_max of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively). A statistically significant difference (P<0.05) was observed for the pharmacokinetic parameters of 97/63 after oral administration of 97/78 alone and upon its coadministration with lamotrigine except for the C_max and T_max values in male and for the T_1/2 value in female rats. Statistically, no significant difference for the pharmacokinetic parameters of 97/63 between male and female rats after oral administration of 97/78 alone or in combination with lamotrigine was determined except for T_max. The study indicates that coadministration of 97/78, an antimalarial agent, and the antiepileptic lamotrigine may require dose adjustments. Additional clinical drug interaction trials may be required to confirm these findings.

• References

• 1 Sperber K, Chiang G, Chen H et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19: 913-923
  CrossrefPubMedGoogle Scholar
• 2 Yuen AWC, Land G, Weatherley B. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-513
  CrossrefPubMedGoogle Scholar
• 3 Besag FM, Berry DJ, Pool F. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998; 39: 183-187
  CrossrefPubMedGoogle Scholar
• 4 Majkowski J. Antiepileptic and nonantiepileptic drug interactions. Epileptologia 1998; 6: 55-73
  PubMedGoogle Scholar
• 5 Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta. Neurol Scand 2003; 108 (180) 16-22
  PubMedGoogle Scholar
• 6 Gupta S, Thapar MM, Wernsdorfer WH. In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob. Agents Chemother 2002; 46: 1510-1515
  CrossrefPubMedGoogle Scholar
• 7 Patsalos PN, Duncan JS. Antiepileptic drugs; a review of clinically significant drug interactions. Drug Saf 1993; 9: 156-184
  CrossrefPubMedGoogle Scholar
• 8 Patsalos PN. Pharmacokinetics and pharmacodynamic interaction; principles and interpretative pitfalls. Epileptologia 1998; 6: 9-19
  PubMedGoogle Scholar
• 9 Patsalos PN. Therapeutic drug monitoring in epilepsy: the established and the new antienilentic drugs. Epilepsy Monit 2002; 6: 1-8
  PubMedGoogle Scholar
• 10 Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics- A treatise. New Delhi: Vallabh Prakashan; 1997
  Google Scholar
• 11 Bonate PL, Reith K, Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet 1998; 34: 375-404
  CrossrefPubMedGoogle Scholar
• 12 Hansten PD. Understanding drug interactions. Sci. Med 1998; Jan/Feb: 16-25
  PubMedGoogle Scholar
• 13 Tanaka E. Clinically important pharmacokinctic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharmacol Ther 1998; 23: 403-416
  CrossrefPubMedGoogle Scholar
• 14 Lundahi J, Regardh CG, Edgar B et al. Effect of grapefruit juice ingestion – pharmacokineties and haemodynamics of intravenously and orally adminisitered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-145
  PubMed
• 15 Lund W. The Pharmaceutical Codex. 12^th edition London: The Pharmaceutical Press; 1994: 342
  Google Scholar
• 16 Welling PG, Tse FLS. Pharmacokinetics, regulatory-industrial-academic perspectives. 2^nd edition. New York: Marcel Dekker Inc; 1995: 335-410
  Google Scholar
• 17 Singh RP, Sabarinath S, Gautam N et al. Liquid chromatographic tandem mass spectrometric assay for quantification of 97/78 and its metabolite 97/63: A promising trioxane antimalarial in monkey plasma. J Chromatogr B 2009; 877: 2074-2080
  CrossrefPubMedGoogle Scholar
• 18 Singh RP, Sabarinath S, Gautam N et al. Pharmacokinetic study of the novel, synthetic trioxane antimalarialcompound 97-78 in rats using an LC-MS/MS method for quantification. Arzneimittelforschung 2011; 61: 120-125
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Shah VP, Midha KK, Findlay JWA et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557
  CrossrefPubMedGoogle Scholar
• 20 Freireich EJ, Gehan EA, Rall DP et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966; 50: 219-244
  PubMedGoogle Scholar
• 21 Tripathi KD. Essentials of Medical Pharmacology. 5^th edition New Delhi: Jaypee Brothers Medical Publishers(P) Ltd; 2010
  Google Scholar
• 22 Bjornsson TD, Callaghan JT, Einolf HJ et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-832
  CrossrefPubMedGoogle Scholar
• 23 Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?. J Clin Pharmacol 2004; 44: 559-569
  CrossrefPubMedGoogle Scholar
• 24 Yuan R, Madani S, Wei XX et al. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30: 1311-1319
  CrossrefPubMedGoogle Scholar
• 25 Davit B, Reynolds K, Yuan R et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999; 39: 899-910
  CrossrefPubMedGoogle Scholar
• 26 Mizuno N, Niwa T, Yotsumoto Y et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425-461
  CrossrefPubMedGoogle Scholar
• 27 Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55: 53-81
  CrossrefPubMedGoogle Scholar
• 28 Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 2002; 17: 253-274
  CrossrefPubMedGoogle Scholar